Registry DAPT data “could support clinical trials”

Robert Yeh

Data captured in the National Cardiovascular Data Registry (NCDR) is similar in quality, depth and granularity when compared to data captured through clinical trials, according to research published in JACC: Cardiovascular Interventions that compared data from the DAPT Study to NCDR CathPCI Registry data.

The finding is “good news” for streamlining data collection and supports recent efforts to standardise data elements and definitions used in clinical trials and registries, according to the American College of Cardiology (ACC).

The researchers, who included Neel Butala (Massachusetts General Hospital and Harvard Medical School, Boston, USA) and senior author Robert Yeh (Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA), linked a group of Dual Antiplatelet Therapy (DAPT) Study patients to the NCDR CathPCI Registry and compared data elements for the same patients.

All patients receiving percutaneous coronary intervention (PCI) with drug-eluting stents randomised in the DAPT Study who could be linked to the CathPCI Registry were included. Baseline patient and procedural characteristics were compared using data collected by two methods: reports submitted by DAPT Study investigators and site-reported data submitted to the CathPCI Registry.

Out of 8,864 DAPT Study patients, 5,743 (65%) were successfully matched to data in the CathPCI Registry. There was strong agreement with many data elements, including demographics and procedural characteristics, the researchers found. For some prior history and risk factors, there was more modest agreement and agreement was poor for clinical presentation. According to the researchers, most notably, angina was more likely to be classified as unstable in the CathPCI Registry versus the DAPT Study.

The results suggest that CathPCI Registry data could be used to support future clinical trials, decreasing the burden of data collection on sites participating in both trials and the registry. However, variables that could be considered more subjective, such as clinical presentation, would likely need to be defined more precisely. Future trials leveraging the CathPCI Registry would also need to ensure that the key data elements are suitable to answer key trial questions.

“We found an overall high level of similarity in data between these two sources. This suggests that registries may also be suitable to support baseline data collection for many clinical studies,” said Yeh. “Being able to leverage existing registries to provide data for clinical trials has the potential to greatly enhance the efficiency and lower the costs of conducting these important studies.”

“Whether these findings generalise to other types of data in the CathPCI Registry or other clinical registries is unknown and remains a rich area for future inquiry,” Yeh said. “Overall, however, the data are promising in pointing to an important mechanism to make clinical trials more feasible and less costly, helping to overcome one of the most significant barriers to clinical research.”

The primary limitations of the study were the inability to link all patients. In addition, how these results would have fared for other clinical trials is unknown.


Please enter your comment!
Please enter your name here